Levetiracetam Tablet, Film Coated, Extended Release
Product Images NDC 50228-190

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50228-190). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sciegen Pharmaceuticals, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levetiracetam 500mg Er Tabs.jpg (Levetiracetam 500mg 30tabs)

Label for Levetiracetam Extended-Release Tablets, USP 500 mg film-coated tablets by ScieGen Pharmaceuticals, Inc. The label indicates once daily dosing and contains 30 tablets in the package. It includes storage instructions, usual dosage guidance, pharmacist dispensing information, and a barcode. The label also shows the NDC number 50228-189-30 and lot and expiration fields.*

FDA Label Image

Levetiracetam 500mg Er Tabs.jpg (Levetiracetam 500mg 500tabs)

Label for Levetiracetam Extended-release Tablets USP 500 mg, film coated extended-release oral tablets. The label indicates once daily dosing and a package size of 500 tablets. Manufactured by ScieGen Pharmaceuticals, Inc. The label includes storage instructions, barcode, and regulatory notes such as the pharmacist dispensing guide and Rx only status.*

FDA Label Image

Levetiracetam 500mg 60tabs

Label for Levetiracetam Extended-Release Tablets, USP 500 mg by ScieGen Pharmaceuticals, Inc. The label includes dosage form as film-coated extended-release tablets, 60 count, prescription only. Storage instructions, dosage reference, and manufacturer details are also present along with a barcode and NDC 50228-189-60.*

FDA Label Image

Levetiracetam 750 mg Er Tabs.jpg (Levetiracetam 750mg 30tabs)

Label for Levetiracetam Extended-Release Tablets, USP, 750 mg strength by ScieGen Pharmaceuticals, Inc. The oral film-coated extended-release tablet package contains 30 tablets. The label includes dosage storage instructions, dispensing guidance, and a barcode, indicating it is for prescription use only.*

FDA Label Image

Levetiracetam 750 mg Er Tabs.jpg (Levetiracetam 750mg 500tabs)

Levetiracetam Extended-Release Tablets USP, 750 mg film-coated oral tablets. The label indicates once daily dosing with a container of 500 tablets. Manufactured by ScieGen Pharmaceuticals, Inc, the label includes storage instructions and pharmacist dispensing information along with the NDC 50228-190-05.*

FDA Label Image

Levetiracetam 750mg 60tabs

Label for Levetiracetam Extended-Release Tablets, USP, 750 mg film-coated tablets by ScieGen Pharmaceuticals, Inc. The label states once daily dosing, contains 60 tablets, and includes storage instructions and dispensing guidelines. The NDC number is 50228-190-60, and the package measures 0.90 by 1.50 inches with no varnish.*

FDA Label Image

Fig1.jpg (Levetiracetam Fig1)

A bar chart depicting the percentage of patients for three groups: Placebo (7.4%), Immediate-release levetiracetam 1,000 mg/day (37.1%), and Immediate-release levetiracetam 3,000 mg/day (39.6%). The y-axis represents the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Fig2.jpg (Levetiracetam Fig2)

A bar graph showing the percentage of patients experiencing effects for three groups: Placebo (6.3%), Immediate-release levetiracetam 1,000 mg/day (20.8%), and Immediate-release levetiracetam 2,000 mg/day (35.2%). The graph indicates statistically significant differences from placebo for the levetiracetam groups.*

FDA Label Image

Fig3.jpg (Levetiracetam Fig3)

A bar chart comparing the percentage of patients between placebo and immediate-release levetiracetam at 3,000 mg/day. The placebo group (N=104) shows 14.4% of patients, while the immediate-release levetiracetam group (N=180) shows 39.4%, with a statistically significant difference indicated.*

FDA Label Image

Fig4.jpg (Levetiracetam Fig4)

A bar chart comparing the percentage of patients between a placebo group (N=97) and an immediate-release levetiracetam tablet group (N=101). The chart shows about 19.6% for placebo and 44.6% for levetiracetam, indicating a statistically significant difference versus placebo.*

FDA Label Image

Levetiracetamxr-01 (Levetiracetam Xr 01)

Chemical structure diagram of levetiracetam, the active ingredient in Levetiracetam Extended-Release tablets by ScieGen Pharmaceuticals, Inc. The structure shows a pyrrolidone ring attached to an ethyl group and an amide functional group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.